Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Myeloid Malignancies: early-phase trial registry
4 of 6 indexed Myeloid Malignancies trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 4 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Myeloid Malignancies: 6 US clinical trials tracked, 4 recruiting.
Myeloid Malignancies is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 4 of these trials.
Enrollment posture brief
Registry condition myeloid-malignancies
OPEN 4 | RECR 67% | LATE 0 | EARLY 6 | RANK #2866 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Adenocarcinoma of Lung (67% recruiting · 6 trials)
Myeloid Malignancies lists 4 open slots (67% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Myeloid Malignancies on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Myeloid Malignancies is recruiting above its size-band peers.
4 of 6 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Myeloid Malignancies research.
M.D. Anderson Cancer Center accounts for 4 of 6 trials (66.7%). 3 distinct sponsors appear on at least one study for this condition label.
-
Most Myeloid Malignancies trials plan to enrol fewer than 100 people.
Median target enrolment is 42 among the 6 trials that report a genuine target (sentinel values excluded). 6 of those (100%) plan for fewer than 100 participants.
-
Myeloid Malignancies research is mostly interventional.
6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies
M.D. Anderson Cancer Center
NCT06383572
A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies
M.D. Anderson Cancer Center
NCT06930651
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
Franziska Wachter
NCT05796570
A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies
M.D. Anderson Cancer Center
NCT06668584
Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis
Geron Corporation
NCT01731951
Off-the-shelf NK Cells + SCT for Myeloid Malignancies
M.D. Anderson Cancer Center
NCT05115630
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Myeloid Malignancies records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Myeloid Malignancies trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Myeloid Malignancies page
6 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Myeloid Malignancies trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Myeloid Malignancies trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Myeloid Malignancies condition card totals 6 registered trials; most-linked intervention Decitabine; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.